Ann: Maiden dosing of TRP-8803 completed in global first, page-4

I think you're right. I was a bit skeptical of IV administration, but I'm slowly being convinced.

Psychedelics are a bit of a problem when it comes to Phase 3 trials, as it's impossible to have a proper control group -- it's quite obvious if you've been given a placebo. So regulators are struggling to know how to separate out placebo effects from genuine effects, which is already pretty difficult in presentations like depression. IV gives that extra level of control in administration that may just give TYP a regulatory advantage.

It's all very interesting anyway. I'm only here as a carryover from the EX1 disaster, but I've been convinced enough to buy more TYP as a bit of a gamble.

Good luck to all!